These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 7966625

  • 1. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
    Fourel I, Cullen JM, Saputelli J, Aldrich CE, Schaffer P, Averett DR, Pugh J, Mason WS.
    J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus.
    Mason WS, Cullen J, Saputelli J, Wu TT, Liu C, London WT, Lustbader E, Schaffer P, O'Connell AP, Fourel I.
    Hepatology; 1994 Feb; 19(2):398-411. PubMed ID: 8294097
    [Abstract] [Full Text] [Related]

  • 3. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.
    Zoulim F, Dannaoui E, Borel C, Hantz O, Lin TS, Liu SH, Trépo C, Cheng YC.
    Antimicrob Agents Chemother; 1996 Feb; 40(2):448-53. PubMed ID: 8834896
    [Abstract] [Full Text] [Related]

  • 4. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver.
    Fourel I, Saputelli J, Schaffer P, Mason WS.
    J Virol; 1994 Feb; 68(2):1059-65. PubMed ID: 8289335
    [Abstract] [Full Text] [Related]

  • 5. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
    Nicoll A, Locarnini S, Chou ST, Smallwood R, Angus P.
    J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
    [Abstract] [Full Text] [Related]

  • 6. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
    Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trépo C, Cheng YC, Zoulim F.
    Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
    [Abstract] [Full Text] [Related]

  • 7. Antiviral effects of PNA in duck hepatitis B virus infection model.
    Chen ZY, Cheng AC, Wang MS, Xu DW, Zeng W, Li Z.
    Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
    [Abstract] [Full Text] [Related]

  • 8. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
    Zoulim F, Berthillon P, Guerhier FL, Seigneres B, Germon S, Pichoud C, Cheng YC, Trepo C.
    J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
    [Abstract] [Full Text] [Related]

  • 9. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
    Tsiquaye KN, Slomka MJ, Maung M.
    J Med Virol; 1994 Mar; 42(3):306-10. PubMed ID: 8006644
    [Abstract] [Full Text] [Related]

  • 10. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
    Miller DS, Boyle D, Feng F, Reaiche GY, Kotlarski I, Colonno R, Jilbert AR.
    Virology; 2008 Apr 10; 373(2):329-41. PubMed ID: 18206204
    [Abstract] [Full Text] [Related]

  • 11. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
    Reaiche GY, Le Mire MF, Mason WS, Jilbert AR.
    Virology; 2010 Oct 25; 406(2):286-92. PubMed ID: 20705309
    [Abstract] [Full Text] [Related]

  • 12. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
    Tomita T, Yokosuka O, Tagawa M, Saisho H, Tamura S, Fukuda I, Omata M.
    J Hepatol; 2000 May 25; 32(5):850-8. PubMed ID: 10845674
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.
    Aguesse-Germon S, Liu SH, Chevallier M, Pichoud C, Jamard C, Borel C, Chu CK, Trépo C, Cheng YC, Zoulim F.
    Antimicrob Agents Chemother; 1998 Feb 25; 42(2):369-76. PubMed ID: 9527788
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.
    Hafkemeyer P, Keppler-Hafkemeyer A, al Haya MA, von Janta-Lipinski M, Matthes E, Lehmann C, Offensperger WB, Offensperger S, Gerok W, Blum HE.
    Antimicrob Agents Chemother; 1996 Mar 25; 40(3):792-4. PubMed ID: 8851615
    [Abstract] [Full Text] [Related]

  • 15. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir.
    Dean J, Bowden S, Locarnini S.
    Antiviral Res; 1995 May 25; 27(1-2):171-8. PubMed ID: 7486954
    [Abstract] [Full Text] [Related]

  • 16. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
    Reaiche-Miller GY, Thorpe M, Low HC, Qiao Q, Scougall CA, Mason WS, Litwin S, Jilbert AR.
    Virology; 2013 Nov 25; 446(1-2):357-64. PubMed ID: 24074600
    [Abstract] [Full Text] [Related]

  • 17. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
    Seignères B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trépo C, Zoulim F.
    Antimicrob Agents Chemother; 2003 Jun 25; 47(6):1842-52. PubMed ID: 12760857
    [Abstract] [Full Text] [Related]

  • 18. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement.
    Jilbert AR, Wu TT, England JM, Hall PM, Carp NZ, O'Connell AP, Mason WS.
    J Virol; 1992 Mar 25; 66(3):1377-88. PubMed ID: 1738197
    [Abstract] [Full Text] [Related]

  • 19. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
    Jilbert AR, Botten JA, Miller DS, Bertram EM, Hall PM, Kotlarski J, Burrell CJ.
    Virology; 1998 May 10; 244(2):273-82. PubMed ID: 9601498
    [Abstract] [Full Text] [Related]

  • 20. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.
    Luscombe C, Pedersen J, Bowden S, Locarnini S.
    Liver; 1994 Aug 10; 14(4):182-92. PubMed ID: 7968278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.